Anthrax lethal and edema toxins in anthrax pathogenesis

Trends in Microbiology

Volumn 22, Issue 6, 2014, Pages 317-325

  Liu, Shihui ^a   Moayeri, Mahtab ^a   Leppla, Stephen H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax; Capillary morphogenesis protein 2; Edema toxin; Lethal toxin; Tumor endothelial marker 8

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTHRAX TOXIN; ANTHRAX VACCINE; CIPROFLOXACIN; COLLAGEN TYPE 4; DOXYCYCLINE; ERYTHROMYCIN; FIBRONECTIN; IMMUNOGLOBULIN FC FRAGMENT; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PENICILLIN DERIVATIVE; RAF PROTEIN; RAS PROTEIN; RAXIBACUMAB; TUMOR ENDOTHELIUM MARKER 8; UNCLASSIFIED DRUG; VANCOMYCIN; ANTHRAX TOXIN RECEPTORS; BACTERIAL ANTIGEN; BACTERIAL TOXIN; RECEPTOR;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; BINDING AFFINITY; BINDING SITE; BONE MARROW CELL; DENDRITIC CELL; DISEASE COURSE; EXTRACELLULAR MATRIX; HEPATITIS B; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC HYALINOSIS; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; PHYSIOLOGY;

ANIMALIA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MODELS, BIOLOGICAL; RECEPTORS, PEPTIDE;

EID: 84901589119     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.02.012     Document Type: Review

References (98)

1. Hudson M.J., et al. Bacillus anthracis: balancing innocent research with dual-use potential. Int. J. Med. Microbiol. 2008, 298:345-364.
2. Leppla S.H. Anthrax lethal factor. Handbook of Proteolytic Enzymes 2013, 1257-1261. Academic Press. 3rd edn. N.D. Rawlings, G.S. Salvesen (Eds.).
3. Fouet A., Mock M. Regulatory networks for virulence and persistence of Bacillus anthracis. Curr. Opin. Microbiol. 2006, 9:160-166.
4. Guidi-Rontani C. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends Microbiol. 2002, 10:405.
5. Corre J.P., et al. In vivo germination of Bacillus anthracis spores during murine cutaneous infection. J. Infect. Dis. 2013, 207:450-457.
6. Okugawa S., et al. Lipoprotein biosynthesis by prolipoprotein diacylglyceryl transferase is required for efficient spore germination and full virulence of Bacillus anthracis. Mol. Microbiol. 2012, 83:96-109.
7. Weiner Z.P., Glomski I.J. Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through Its host. Infect. Immun. 2012, 80:1626-1633.
8. Moayeri M., Leppla S.H. Anthrax toxins. Bacillus anthracis and anthrax (1st edn) 2011, 121-156. John Wiley & Sons. N.H. Bergman (Ed.).
9. Kintzer A.F., et al. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 2009, 392:614-629.
10. Phillips D.D., et al. Engineering anthrax toxin variants that exclusively form octamers, and their application to targeting tumors. J. Biol. Chem. 2013, 288:9058-9065.
11. Young J.A., Collier R.J. Anthrax toxin: receptor-binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76:243-265.
12. Abrami L., et al. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 2003, 160:321-328.
13. Collier R.J. Membrane translocation by anthrax toxin. Mol. Aspects Med. 2009, 30:413-422.
14. Van Der Goot G., Young J.A. Receptors of anthrax toxin and cell entry. Mol. Aspects Med. 2009, 30:406-412.
15. Liu S., Leppla S.H. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 2003, 278:5227-5234.
16. Bradley K.A., et al. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414:225-229.
17. Scobie H.M., et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5170-5174.
18. Cryan L.M., Rogers M.S. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front. Biosci. 2011, 16:1574-1588.
19. Chaudhary A., et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 2012, 21:212-226.
20. Bell S.E., et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 2001, 114:2755-2773.
21. Deuquet J., et al. The dark sides of capillary morphogenesis gene 2. EMBO J. 2012, 31:3-13.
22. Stranecky V., et al. Mutations in ANTXR1 cause GAPO syndrome. Am. J. Hum. Genet. 2013, 92:792-799.
23. Cullen M., et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res. 2009, 69:6021-6026.
24. Liu S., et al. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12424-12429.
25. Reeves C.V., et al. Anthrax toxin receptor 2 functions in ECM homeostasis of the murine reproductive tract and promotes MMP activity. PLoS ONE 2012, 7:e34862.
26. Peters D.E., et al. Capillary morphogenesis protein-2 is required for mouse parturition by maintaining uterine collagen homeostasis. Biochem. Biophys. Res. Commun. 2012, 422:393-397.
27. Liu S., et al. The receptors that mediate the direct lethality of anthrax toxin. Toxins (Basel) 2012, 5:1-8.
28. Martchenko M., et al. Heterodimeric integrin complexes containing β1-integrin promote internalization and lethality of anthrax toxin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15583-15588.
29. Wei W., et al. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 2006, 124:1141-1154.
30. Young J.J., et al. LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog. 2007, 3:e27.
31. Ryan P.L., Young J.A. Evidence against a human cell-specific role for LRP6 in anthrax toxin entry. PLoS ONE 2008, 3:e1817.
32. Moayeri M., et al. Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Infect. Immun. 2007, 75:5175-5184.
33. Vuyisich M., et al. Binding and cell intoxication studies of anthrax lethal toxin. Mol. Biol. Rep. 2012, 39:5897-5903.
34. Duesbery N.S., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280:734-737.
35. Lee C.S., et al. MEK2 Is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. PLoS ONE 2011, 6:e17165.
36. Vitale G., et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998, 248:706-711.
37. Vitale G., et al. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000, 352:739-745.
38. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
39. Bollag G., et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 2012, 11:873-886.
40. Abi-Habib R.J., et al. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol. Cancer Ther. 2005, 4:1303-1310.
41. Schafer J.M., et al. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS ONE 2011, 6:e20532.
42. Liu S., et al. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat. Biotechnol. 2005, 23:725-730.
43. Liu S., et al. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem. 2008, 283:529-540.
44. Kassab E., et al. Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Transl. Oncol. 2013, 6:25-32.
45. Newman Z.L., et al. Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages. Biochem. Biophys. Res. Commun. 2010, 398:785-789.
46. Newman Z.L., et al. Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLoS Pathog. 2010, 6:e1000906.
47. Levinsohn J.L., et al. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 2012, 8:e1002638.
48. Hellmich K.A., et al. Anthrax lethal factor cleaves mouse Nlrp1b in both toxin-sensitive and toxin-resistant macrophages. PLoS ONE 2012, 7:e49741.
49. Chavarria-Smith J., Vance R.E. Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog. 2013, 9:e1003452.
50. Moayeri M., et al. Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 2003, 112:670-682.
51. Moayeri M., et al. Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect. Immun. 2004, 72:4439-4447.
52. Moayeri M., et al. Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog. 2010, 6:e1001222.
53. Terra J.K., et al. Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J. Immunol. 2010, 184:17-20.
54. Firoved A.M., et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 2005, 167:1309-1320.
55. Liu S., et al. Key tissue targets responsible for anthrax-toxin-induced lethality. Nature 2013, 501:63-68.
56. Dal Molin F., et al. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 2008, 52:824-828.
57. Mabry R., et al. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin. Vaccine Immunol. 2006, 13:671-677.
58. Muanprasat C., Chatsudthipong V. Cholera: pathophysiology and emerging therapeutic targets. Future Med. Chem. 2013, 5:781-798.
59. Schmidt M., et al. Exchange protein directly activated by cAMP (Epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol. Rev. 2013, 65:670-709.
60. Kirschner L.S., et al. Mouse models of altered protein kinase A signaling. Endocr. Relat. Cancer 2009, 16:773-793.
61. Yan J., et al. Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1. Mol. Cell. Biol. 2013, 33:918-926.
62. Song W.J., et al. Pancreatic beta-cell response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A. Diabetes 2013, 62:2796-2807.
63. Shen Y., et al. Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J. 2002, 21:6721-6732.
64. Guichard A., et al. Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature 2010, 467:854-858.
65. Guichard A., et al. Cholera toxin disrupts barrier function by inhibiting exocyst-mediated trafficking of host proteins to intestinal cell junctions. Cell Host Microbe 2013, 14:294-305.
66. Maldonado-Arocho F.J., et al. Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Mol. Microbiol. 2006, 61:324-337.
67. Sastalla I., et al. Anthrax edema toxin impairs protein clearance in mice. Infect. Immun. 2011, 80:529-538.
68. Gottle M., et al. Bacillus anthracis edema factor substrate specificity: Evidence for new modes of action. Toxins (Basel) 2012, 4:505-535.
69. Tournier J.N., et al. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev. Anti Infect. Ther. 2009, 7:219-236.
70. Liu S., et al. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 2010, 8:455-462.
71. Weiner Z.P., et al. Circulating lethal toxin decreases the ability of neutrophils to respond to Bacillus anthracis. Cell. Microbiol. 2013, 10.1111/cmi.12232.
72. Dumetz F., et al. Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am. J. Pathol. 2011, 178:2523-2535.
73. Tournier J.N., et al. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 2009, 30:456-466.
74. Gnade B.T., et al. Emergence of anthrax edema toxin as a master manipulator of macrophage and B cell functions. Toxins (Basel) 2010, 2:1881-1897.
75. Turk B.E. Manipulation of host signalling pathways by anthrax toxins. Biochem. J. 2007, 402:405-417.
76. Baldari C.T., et al. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 2006, 27:434-440.
77. Goossens P.L. Animal models of human anthrax: the quest for the Holy Grail. Mol. Aspects Med. 2009, 30:467-480.
78. Ghosh C.C., et al. Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10024-10029.
79. Bolcome R.E., et al. Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2439-2444.
80. Moayeri M., et al. The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS). PLoS. Pathog. 2009, 4:e1000456.
81. Xie T., et al. The effects of anthrax lethal toxin on host barrier function. Toxins (Basel) 2011, 3:591-607.
82. Fang H., et al. Neutrophil elastase mediates pathogenic effects of anthrax lethal toxin in the murine intestinal tract. J. Immunol. 2010, 185:5463-5467.
83. Golden H.B., et al. Anthrax toxin: pathologic effects on the cardiovascular system. Front. Biosci. 2009, 14:2335-2357.
84. Maddugoda M.P., et al. cAMP signaling by anthrax edema toxin induces transendothelial cell tunnels, which are resealed by MIM via Arp2/3-driven actin polymerization. Cell Host Microbe 2011, 10:464-474.
85. Coggeshall K.M., et al. The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. J. Cell. Mol. Med. 2013, 17:914-920.
86. Artenstein A.W., Opal S.M. Novel approaches to the treatment of systemic anthrax. Clin. Infect. Dis. 2012, 54:1148-1161.
87. Abrami L., et al. Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin. Cell Rep. 2013, 5:986-996.
88. Walsh J.J., et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 2007, 44:968-971.
89. Mazumdar S. Raxibacumab. MAbs 2009, 1:531-538.
90. Chen Z., et al. Monoclonal antibody therapies against anthrax. Toxins 2011, 3:1004-1019.
91. Wycoff K.L., et al. Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax. Antimicrob. Agents Chemother. 2011, 55:132-139.
92. Moayeri M., et al. Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection. Antimicrob. Agents Chemother. 2013, 57:4139-4145.
93. Shen Y., et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3242-3247.
94. Li Y., et al. B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H238-H250.
95. Friedlander A.M., Little S.F. Advances in the development of next-generation anthrax vaccines. Vaccine 2009, 27(Suppl. 4):D28-D32.
96. Kaur M., et al. Anthrax vaccines: present status and future prospects. Expert Rev. Vaccines 2013, 12:955-970.
97. Manish M., et al. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS ONE 2013, 8:e61885.
98. Yin Y., et al. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine. Immunobiology 2014, 219:97-103.